



# *In Vitro* Activity of Ceftolozane-Tazobactam and Other Antimicrobial Agents against *Burkholderia cepacia* Complex and *Burkholderia gladioli*

Dale M. Mazer,<sup>a</sup> Carol Young,<sup>b</sup> Linda M. Kalikin,<sup>c</sup> Theodore Spilker,<sup>c</sup> John J. LiPuma<sup>c</sup>

Departments of Internal Medicine,<sup>a</sup> Pathology,<sup>b</sup> and Pediatrics and Communicable Diseases,<sup>c</sup> University of Michigan Medical School, Ann Arbor, Michigan, USA

**ABSTRACT** We tested the activities of ceftolozane-tazobactam and 13 other antimicrobial agents against 221 strains of *Burkholderia cepacia* complex and *Burkholderia gladioli*. Most strains (82%) were cultured from persons with cystic fibrosis, and most (85%) were recovered since 2011. The ceftolozane-tazobactam MIC was  $\leq 8$   $\mu\text{g/ml}$  for 77% of the strains. However, the MIC range was broad ( $\leq 0.5$  to  $>64$   $\mu\text{g/ml}$ ; MIC<sub>50/90</sub>, 2/32  $\mu\text{g/ml}$ ). Significant differences in susceptibility to some antimicrobial agents were observed between species.

**KEYWORDS** *Burkholderia*, ceftolozane, cystic fibrosis

The 20 species in the *Burkholderia cepacia* complex (Bcc) and the closely related species *Burkholderia gladioli* are Gram-negative nonfermenting bacilli that cause opportunistic infections in susceptible hosts, particularly persons with cystic fibrosis (CF) or chronic granulomatous disease. Respiratory tract infection with *Burkholderia cenocepacia*, *Burkholderia multivorans* (both members of the Bcc), or *B. gladioli* accounts for the majority of *Burkholderia* infections in CF patients (1). Infection is often refractory to therapy, as most *Burkholderia* strains are resistant to available antimicrobial agents. Thus, there is a need to explore the utility of newer antimicrobials for their activity against *Burkholderia* species.

Ceftolozane-tazobactam is a combination cephalosporin-beta lactamase inhibitor approved by the Food and Drug Administration in 2014 for treatment of complicated intra-abdominal and complicated urinary tract infections. It has been shown to have good activity against antimicrobial-resistant Gram-negative pathogens, including *Enterobacteriaceae* and *Pseudomonas aeruginosa* (2–5). Studies evaluating ceftolozane-tazobactam activity against bacteria recovered from patients with CF have been limited (2, 6), and we are aware of no studies that specifically focused on activity against *Burkholderia* species. Further, no data have been published regarding differences in susceptibilities to ceftolozane-tazobactam between species within the Bcc.

We tested the activities of ceftolozane-tazobactam and 13 comparator antimicrobial agents against 221 Bcc and *B. gladioli* isolates from the strain collection of the *Burkholderia cepacia* Research Laboratory and Repository at the University of Michigan. All strains had been identified to the species level using genetically based methods previously described (7), and all were distinct by genotyping analyses (8). The strains were recovered from 221 patients receiving care in 122 medical centers in 91 cities in 41 U.S. states and Toronto, Ontario, Canada. Most strains (82%) were recovered from respiratory specimens from CF patients. All were recovered between 2005 and 2016, with the majority (85%) being isolated between 2011 and 2016. The distribution of *Burkholderia* species included in this set reflected that found in CF patients; *B. ceno-*

Received 11 April 2017 Returned for modification 15 May 2017 Accepted 25 June 2017

Accepted manuscript posted online 3 July 2017

**Citation** Mazer DM, Young C, Kalikin LM, Spilker T, LiPuma JJ. 2017. *In vitro* activity of ceftolozane-tazobactam and other antimicrobial agents against *Burkholderia cepacia* complex and *Burkholderia gladioli*. *Antimicrob Agents Chemother* 61:e00766-17. <https://doi.org/10.1128/AAC.00766-17>.

**Copyright** © 2017 American Society for Microbiology. All Rights Reserved.

Address correspondence to John J. LiPuma, [jlipuma@umich.edu](mailto:jlipuma@umich.edu).

**TABLE 1** Activities of ceftolozane-tazobactam and comparator agents against *Burkholderia* strains

Species or group (n <sup>a</sup> )	Antibiotic(s)	MICs (μg/ml)		
		Range	MIC <sub>50</sub>	MIC <sub>90</sub>
<i>Burkholderia</i> , all isolates (221)	Ceftolozane-tazobactam	≤0.25 to >64	2	32
	Amikacin	≤16 to >64	64	>64
	Aztreonam	≤4 to >32	16	>32
	Ceftazidime	≤0.5 to >64	4	16
	Chloramphenicol	≤8 to >32	16	32
	Ciprofloxacin	≤2 to >8	≤2	>8
	Doripenem	≤1 to >8	4	8
	Levofloxacin	≤1 to >8	≤1	>8
	Meropenem	≤1 to >16	2	8
	Minocycline	≤1 to >16	2	8
	Piperacillin-tazobactam	≤4 to >128	≤4	128
	Tigecycline	≤2 to 16	≤2	8
	Tobramycin	≤2 to >16	>16	>16
Trimethoprim-sulfamethoxazole	≤1 to >8	≤1	2	
<i>Burkholderia multivorans</i> (50)	Ceftolozane-tazobactam	0.5 to >64	1	>64
	Amikacin	≤16 to >64	64	>64
	Aztreonam	≤4 to >32	≤4	>32
	Ceftazidime	1 to >64	2	64
	Chloramphenicol	≤8 to >32	≤8	32
	Ciprofloxacin	≤2 to >8	≤2	>8
	Doripenem	≤1 to >8	4	8
	Levofloxacin	≤1 to >8	≤1	>8
	Meropenem	≤1 to >16	4	>16
	Minocycline	≤1 to 16	<1	4
	Piperacillin-tazobactam	≤4 to >128	≤4	>128
	Tigecycline	≤2 to 16	≤2	8
	Tobramycin	≤2 to >16	>16	>16
Trimethoprim-sulfamethoxazole	≤1 to 8	≤1	2	
<i>Burkholderia cenocepacia</i> (42)	Ceftolozane-tazobactam	≤0.25 to >64	1	32
	Amikacin	≤16 to >64	>64	>64
	Aztreonam	≤4 to >32	16	>32
	Ceftazidime	1 to >64	4	16
	Chloramphenicol	≤8 to >32	16	>32
	Ciprofloxacin	≤2 to >8	≤2	>8
	Doripenem	≤1 to >8	4	>8
	Levofloxacin	≤1 to >8	2	>8
	Meropenem	≤1 to 16	2	8
	Minocycline	≤1 to >16	2	16
	Piperacillin-tazobactam	≤4 to >128	8	128
	Tigecycline	≤2 to 16	≤2	16
	Tobramycin	8 to >16	>16	>16
Trimethoprim-sulfamethoxazole	≤1 to 8	≤1	4	
<i>Burkholderia vietnamiensis</i> (22)	Ceftolozane-tazobactam	≤0.25 to 32	1	4
	Amikacin	≤16 to >64	≤16	>64
	Aztreonam	≤4 to >32	≤4	16
	Ceftazidime	1 to 16	2	4
	Chloramphenicol	≤8 to >32	16	>32
	Ciprofloxacin	≤2 to >8	≤2	4
	Doripenem	≤1 to 8	≤1	4
	Levofloxacin	≤1 to >8	2	8
	Meropenem	≤1 to 4	≤1	4
	Minocycline	≤1 to 8	2	4
	Piperacillin-tazobactam	≤4 to 128	≤4	16
	Tigecycline	≤2 to >16	≤2	4
	Tobramycin	≤2 to >16	8	>16
Trimethoprim-sulfamethoxazole	≤1 to >8	≤1	8	
<i>Burkholderia cepacia</i> (22)	Ceftolozane-tazobactam	0.5 to 4	1	4
	Amikacin	32 to >64	32	>64
	Aztreonam	8 to >32	16	>32
	Ceftazidime	2 to 16	4	8

(Continued on following page)

TABLE 1 (Continued)


Species or group (n <sup>a</sup> )	Antibiotic(s)	MICs (μg/ml)		
		Range	MIC <sub>50</sub>	MIC <sub>90</sub>
	Chloramphenicol	≤8 to >32	16	32
	Ciprofloxacin	≤2 to 4	≤2	≤2
	Doripenem	4 to 8	4	8
	Levofloxacin	≤1 to 8	2	4
	Meropenem	2 to 8	4	4
	Minocycline	≤1 to 16	2	4
	Piperacillin-tazobactam	≤4 to 128	8	32
	Tigecycline	≤2 to 16	≤2	4
	Tobramycin	16 to >16	>16	>16
	Trimethoprim-sulfamethoxazole	≤1	≤1	≤1
Other Bcc spp. <sup>b</sup> (39)	Ceftolozane-tazobactam	≤0.25 to >64	2	16
	Amikacin	≤16 to >64	64	>64
	Aztreonam	≤4 to >32	16	>32
	Ceftazidime	≤0.5 to >64	4	16
	Chloramphenicol	≤8 to >32	16	32
	Ciprofloxacin	≤2 to >8	≤2	4
	Doripenem	≤1 to >8	4	8
	Levofloxacin	≤1 to >8	≤1	4
	Meropenem	≤1 to >16	4	8
	Minocycline	≤1 to >16	2	8
	Piperacillin-tazobactam	≤4 to 128	8	128
	Tigecycline	≤2 to 16	≤2	8
	Tobramycin	≤2 to >16	>16	>16
	Trimethoprim-sulfamethoxazole	≤1 to 4	≤1	≤1
<i>Burkholderia gladioli</i> (46)	Ceftolozane-tazobactam	2 to 32	8	16
	Amikacin	≤16 to 64	≤16	≤16
	Aztreonam	16 to >32	32	>32
	Ceftazidime	1 to 64	16	16
	Chloramphenicol	≤8 to >32	32	32
	Ciprofloxacin	≤2 to >8	≤2	≤2
	Doripenem	≤1 to 4	≤1	2
	Levofloxacin	≤1 to >8	≤1	2
	Meropenem	≤1 to 8	≤1	2
	Minocycline	≤1 to 16	2	4
	Piperacillin-tazobactam	≤4 to 64	≤4	≤4
	Tigecycline	≤2 to 16	≤2	≤2
	Tobramycin	≤2 to >16	≤2	≤2
	Trimethoprim-sulfamethoxazole	≤1 to 2	≤1	≤1

<sup>a</sup>Number tested in each category.

<sup>b</sup>Includes (number of isolates) *Burkholderia contaminans* (11), *Burkholderia dolosa* (10), *Burkholderia ambifaria* (9), and *Burkholderia stabilis* (9).

*pacia*, *B. multivorans*, and *B. gladioli* accounted for 62% of the strains (1). Ceftolozane-tazobactam MIC values were determined, in triplicate, using the reference Clinical and Laboratory Standards Institute broth microdilution method (9), and custom-dried antibiotic plates were read on a Sensititre ARIS instrument (Thermo Scientific).

The results of susceptibility testing are summarized in Table 1. Ceftolozane-tazobactam demonstrated good overall activity (MIC<sub>50</sub>, 2 μg/ml; MIC<sub>90</sub>, 32 μg/ml) against the 221 *Burkholderia* strains tested. Although the range of inhibitory activities was broad (MIC range, ≤0.25 to >64 μg/ml), 77% of the strains were inhibited by concentrations of ≤8 μg/ml, which was comparable to the activity demonstrated by ceftazidime, arguably the most relevant drug among the comparator agents tested; 76% of the strains were susceptible (MICs, ≤8 μg/ml) to ceftazidime. Further, ceftolozane-tazobactam was at least 2-fold more active than ceftazidime against 82% of ceftazidime-susceptible strains and at least 4-fold more active against 33% of these strains (Fig. 1). In contrast, ceftazidime was at least 2-fold more active than ceftolozane-tazobactam against only 5% of ceftazidime-susceptible strains and at least 4-fold more active against only 3% of these strains. When MIC<sub>50</sub> values were used, ceftolozane-tazobactam showed potency equivalent to that of meropenem and minocycline (MIC<sub>50</sub>



**FIG 1** Distribution of MICs of ceftolozane-tazobactam, ceftazidime, and meropenem for 221 *Burkholderia* strains.

for all three agents, 2 µg/ml). Ceftolozane-tazobactam showed good activities (MICs, ≤8 µg/ml) against 19 (76%) of the 25 multidrug-resistant (MDR) (10) strains in the test set and against 5 (25%) of the 20 extensively drug-resistant (10) strains. Other agents retaining activities against the MDR strains included ceftazidime (MIC<sub>50</sub>, 4 µg/ml; 50% susceptible), meropenem (MIC<sub>50</sub>, 4 µg/ml; 64% susceptible), piperacillin-tazobactam (MIC<sub>50</sub>, 16 µg/ml), and trimethoprim-sulfamethoxazole (MIC<sub>50</sub>, ≤1 µg/ml; 80% susceptible).

The activities of ceftolozane-tazobactam varied between species within the Bcc. Most notable were the at least 8-fold-poorer activities against *B. cenocepacia* (MIC<sub>90</sub>, 32 µg/ml) and *B. multivorans* (MIC<sub>90</sub>, >64 µg/ml) relative to those against all other Bcc species tested (MIC<sub>90</sub>, 4 µg/ml). Other noteworthy differences of the comparator drugs against strains in the test panel included (i) the greater activities of ceftazidime and piperacillin-tazobactam against *Burkholderia vietnamiensis* strains (MIC<sub>90S</sub>, 4 µg/ml and 16 µg/ml, respectively) relative to those against all other Bcc species (MIC<sub>90S</sub>, 16 µg/ml and >128 µg/ml, respectively) and (ii) the greater activities (based on MIC<sub>90</sub> values) of piperacillin-tazobactam, tigecycline, and the quinolone and carbapenem antibiotics against *B. gladioli* compared to those against the Bcc species. The activities of the aminoglycoside antibiotics against *B. gladioli*, which are in stark contrast to the very poor activities of this class of antibiotics against Bcc species, are well-known distinguishing features of *B. gladioli* (11).

Although interpretive criteria for ceftolozane-tazobactam susceptibility testing of *Burkholderia* spp. are not yet established, the MICs of this combination antimicrobial were in a range comparable to those of other agents used to treat *Burkholderia* infections. It demonstrated marginally superior activity over that of ceftazidime against ceftazidime-susceptible strains and retained activity against most (60%) multidrug-resistant and extensively drug-resistant strains in the test set. Although the Food and Drug Administration does not include infection with *Burkholderia* in its list of indications for ceftolozane-tazobactam, these results suggest that this combination agent offers a potentially effective additional therapy for the management of *Burkholderia* infection in CF patients.

#### ACKNOWLEDGMENTS

This study was supported in part by a research grant from the Investigator Initiated Studies Program of Merck & Co., Inc., Kenilworth, NJ, USA.

The opinions expressed in this paper are those of the authors and do not necessarily represent those of Merck & Co., Inc.

## REFERENCES

1. LiPuma JJ. 2010. The changing microbial epidemiology in cystic fibrosis. *Clin Microbiol Rev* 23:299–323. <https://doi.org/10.1128/CMR.00068-09>.
2. Grohs P, Taieb G, Morand P, Kaibi I, Podglajen I, Lavollay M, Mainardi JL, Compain F. 17 January 2017. In vitro activity of ceftolozane-tazobactam against multidrug-resistant non-fermenting Gram-negative bacilli isolated from patients with cystic fibrosis. *Antimicrob Agents Chemother* <https://doi.org/10.1128/AAC.02688-16>.
3. Snyderman DR, McDermott LA, Jacobus NV. 2014. Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates. *Antimicrob Agents Chemother* 58:1218–1223. <https://doi.org/10.1128/AAC.02253-13>.
4. Farrell DJ, Flamm RK, Sader HS, Jones RN. 2013. Antimicrobial activity of ceftolozane-tazobactam tested against *Enterobacteriaceae* and *Pseudomonas aeruginosa* with various resistance patterns isolated in U.S. hospitals (2011-2012). *Antimicrob Agents Chemother* 57:6305–6310. <https://doi.org/10.1128/AAC.01802-13>.
5. Craig WA, Andes DR. 2013. *In vivo* activities of ceftolozane, a new cephalosporin, with and without tazobactam against *Pseudomonas aeruginosa* and *Enterobacteriaceae*, including strains with extended-spectrum  $\beta$ -lactamases, in the thighs of neutropenic mice. *Antimicrob Agents Chemother* 57:1577–1582. <https://doi.org/10.1128/AAC.01590-12>.
6. Kuti JL, Pettit RS, Neu N, Cies JJ, Lapin C, Muhlebach MS, Novak KJ, Nguyen KJ, Nguyen ST, Saiman L, Nicolau DP. 2015. Microbiologic activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against *Pseudomonas aeruginosa* isolated from children with cystic fibrosis. *Diagn Microbiol Infect Dis* 83:53–55. <https://doi.org/10.1016/j.diagmicrobio.2015.04.012>.
7. Payne GW, Vandamme P, Morgan SH, LiPuma JJ, Coenye T, Weightman AJ, Jones TH, Mahenthiralingam E. 2005. Development of a *recA* gene-based identification approach for the entire *Burkholderia* genus. *Appl Environ Microbiol* 71:3917–3927. <https://doi.org/10.1128/AEM.71.7.3917-3927.2005>.
8. Coenye T, Spilker T, Martin A, LiPuma JJ. 2002. Comparative assessment of genotyping methods for epidemiologic study of *Burkholderia cepacia* genomovar III. *J Clin Microbiol* 40:3300–3307. <https://doi.org/10.1128/JCM.40.9.3300-3307.2002>.
9. Clinical and Laboratories Standards Institute. 2016. Performance standards for antimicrobial susceptibility testing; 26th ed. CLSI Guideline M100. Clinical and Laboratories Standards Institute, Wayne, PA.
10. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. 2012. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect* 18:268–281. <https://doi.org/10.1111/j.1469-0691.2011.03570.x>.
11. Segonds C, Clavel-Batut P, Thouverez M, Grenet D, Le Coustumier A, Plésiat P, Chabanon G. 2009. Microbiological and epidemiological features of clinical respiratory isolates of *Burkholderia gladioli*. *J Clin Microbiol* 47:1510–1516. <https://doi.org/10.1128/JCM.02489-08>.